Marrow Therapeutics launched with substantial venture support to create an improved treatment option for sickle cell disease. Founded by biotech entrepreneur Romesh Subramanian, the company hopes to match the clinical power of existing gene therapies while sidestepping their known downsides. The startup secured $173 million through combined Series A and Series B funding rounds backed by OrbiMed, venBio, and Scion Life Sciences. Although Subramanian acknowledges the scientific approach still requires clinical validation, expectations remain high for its performance.
Key points
Marrow Therapeutics aims to match gene therapy effectiveness while avoiding the drawbacks…: Marrow Therapeutics aims to match gene therapy effectiveness while avoiding the drawbacks linked to it.
The company faces the critical challenge of clinically proving its novel therapeutic appr…: The company faces the critical challenge of clinically proving its novel therapeutic approach in patients.
Strong backing from multiple life science investors provides substantial capital for the…: Strong backing from multiple life science investors provides substantial capital for the new development effort.
Sources checked by our analysis pipeline: 1
For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks.
Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed and others.
“We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Physician-scientist John Powers III has taken permanent leadership of the National Institute of Allergy and Infectious Diseases following the contentious departure of Jeanne Marrazzo in 2025. Having previously served as acting director since June, he favors redirecting research resources away from HIV and pandemic readiness toward wider immunology initiatives alongside the broader agency leadership.
British health authorities have chosen to waive an approaching break clause that would have permitted an early departure from the massive data analytics agreement. This decision ensures that the technology firm remains an integral data partner for the healthcare system across the latter half of the decade. The shift establishes an expected five-year operational horizon rather than an immediate exit.
Palestinian officials and the Israeli military have offered starkly conflicting accounts following a fatal confrontation linked to a newly established settler outpost in al-Duyuk al-Tahta. While local reports state Israeli settlers initiated gunfire outside a family residence, the Israel Defense Forces maintained that Israelis discharged weapons in self-defense following a deliberate vehicle ramming and physical assault. The deadly event coincides with mounting international scrutiny and fresh British economic pen…